Basal Cell Carcinoma

What is Basal Cell Carcinoma?
Clinical Subtypes
Risk Factors
Pathogenesis: Hedgehog Pathway
Diagnosis and Dermoscopy
Treatment Options
Mohs Micrographic Surgery
Advanced and Metastatic BCC
Prognosis and Recurrence
Prevention and Surveillance
Research Papers
Connections
Featured Videos

What is Basal Cell Carcinoma?

Basal cell carcinoma (BCC) is the most common cancer in humans, accounting for approximately 3.5 million new cases per year in the United States alone and roughly 80% of all non-melanoma skin cancers. It arises from basal cells — the deepest layer of the epidermis — and almost always develops on sun-exposed skin, with the head and neck accounting for about 85% of cases.

Despite its extraordinary prevalence, BCC is rarely life-threatening. It grows slowly, destroys local tissue if left untreated, but metastasizes in fewer than 0.1% of cases. The danger lies not in spread but in local invasion: neglected BCCs on the face can erode into bone, cartilage, nerves, and the orbit. The defining principle of BCC management is therefore: cure it completely the first time, because recurrent BCC is substantially harder to treat.

Fair-skinned individuals (Fitzpatrick phototypes I and II) who burn easily and rarely tan carry the highest lifetime risk, with cumulative UV exposure being the primary driver. Lifetime risk for fair-skinned Americans is estimated at 30%.

Clinical Subtypes

Nodular BCC (Most Common)

Nodular BCC accounts for roughly 60–80% of all BCCs. It presents as a pearly or translucent papule or nodule with a rolled (raised) border and visible telangiectasias (dilated blood vessels) on the surface. Over time it may develop a central ulcer — the classic "rodent ulcer" appearance. It occurs most often on the head and neck. The rolled border and pearly sheen distinguish it from squamous cell carcinoma.

Superficial BCC

Superficial BCC appears as a flat, erythematous (red), scaly patch — often mistaken for eczema or psoriasis. It favors the trunk and shoulders and grows slowly along the surface rather than into deeper tissue. It responds well to topical treatments (imiquimod, 5-fluorouracil) and photodynamic therapy for low-risk lesions, though surgical excision remains the most reliable option.

Morpheaform (Sclerosing) BCC

Morpheaform BCC is the most aggressive subtype. It appears as a flat, scar-like, indurated plaque with ill-defined borders — it often looks more like a scar than a cancer. Because its edges are indistinct both clinically and histologically, standard excision margins are frequently inadequate. Mohs surgery is strongly preferred. Perineural invasion and subclinical extension make this subtype prone to recurrence.

Basosquamous (Metatypical) BCC

A rare subtype that shares features of both BCC and squamous cell carcinoma. It carries a higher metastatic potential (though still rare) and should be treated aggressively.

Risk Factors

Fitzpatrick skin type I–II: Blue or green eyes, fair skin, light hair, tendency to burn rather than tan. Melanin is the primary natural protection against UV-induced DNA damage.
Cumulative UV exposure: Unlike melanoma (where intense intermittent burns dominate), BCC risk tracks cumulative lifetime sun exposure — the reason it is so common on the faces of older adults who worked outdoors.
Tanning bed use: Indoor UV tanning increases BCC risk by approximately 69% (IARC classification: Group 1 carcinogen).
Prior skin cancer: Having one BCC increases the risk of a subsequent BCC by 44% within 3 years.
Immunosuppression: Organ transplant recipients have a 10-fold increased risk; long-term immunosuppressive medications (cyclosporine, azathioprine) impair tumor immune surveillance.
Ionizing radiation: Prior radiation therapy to the skin, even decades earlier, predisposes to BCC at the irradiated site.
Arsenic exposure: Chronic arsenic ingestion (historically from contaminated well water or industrial exposure) causes Bowen disease and BCC, particularly on non-sun-exposed sites.
Gorlin syndrome (Nevoid BCC syndrome): An autosomal dominant PTCH1 mutation causing hundreds to thousands of BCCs beginning in early adulthood, jaw cysts, skeletal anomalies, and increased medulloblastoma risk.

Pathogenesis: Hedgehog Pathway

The molecular driver of virtually all BCCs is aberrant activation of the Sonic Hedgehog (SHH) signaling pathway. Under normal conditions:

PTCH1 (Patched-1) protein inhibits Smoothened (SMO), keeping the pathway off.
SHH ligand binds PTCH1, releasing SMO inhibition.
Active SMO drives transcription of GLI family genes, promoting cell proliferation.

In BCC, UV-induced mutations in PTCH1 (loss-of-function, present in ~90% of BCCs) or activating mutations in SMO (~10%) constitutively activate the pathway regardless of SHH ligand. Cells proliferate without the normal restraining signal.

This pathway is the basis for targeted therapy: vismodegib and sonidegib are both SMO inhibitors — they block the constitutively active SMO and suppress BCC growth. They are approved for locally advanced or metastatic BCC where surgery is not feasible.

Additionally, UV causes characteristic C→T transitions at dipyrimidine sites (the "UV signature") in TP53 in approximately 50% of BCCs, further disabling tumor suppression.

Diagnosis and Dermoscopy

The clinical diagnosis of BCC is made by visual inspection and confirmed by skin biopsy (shave, punch, or excisional). Dermoscopy — using a hand-held dermatoscope to examine subsurface skin structures — significantly improves diagnostic accuracy and can often identify BCC before it is clinically obvious.

Dermoscopic Features of BCC

Arborizing vessels: Large, bright-red, branching telangiectasias with a tree-branch pattern — the single most specific dermoscopic feature of nodular BCC. Absent in melanoma and SCC.
Leaf-like areas: Brown-gray discrete leaf-like or petal-like projections at the periphery — hallmark of pigmented BCC.
Blue-gray ovoid nests: Large, well-defined blue-gray structures — characteristic of pigmented BCC.
Spoke-wheel areas: Radial projections with a well-defined center — seen in superficial BCC.
Ulceration: Central erosion with a red-white "structureless" area in nodular BCC.
Shiny white structures: Chrysalis-like or white streaks under polarized light — associated with fibrotic subtypes including morpheaform.

Confocal reflectance microscopy and optical coherence tomography (OCT) are emerging non-invasive imaging tools for pre-operative margin assessment, though biopsy remains the gold standard for histologic subtype classification.

Treatment Options

Electrodesiccation and Curettage (ED&C)

ED&C involves scraping the tumor away with a curette followed by electrocautery to destroy the base, typically repeated three times in the same sitting. It is appropriate for low-risk BCCs on the trunk and extremities — primary, well-defined, nodular or superficial subtypes, diameter <2 cm, not on the face. Cure rates exceed 95% for carefully selected low-risk lesions. The wound heals by secondary intention, leaving a hypopigmented scar. It is not appropriate for morpheaform BCC, recurrent disease, or high-risk anatomical locations.

Standard Surgical Excision

Excision with histologically confirmed clear margins is appropriate for most BCCs. Recommended margins by subtype:

Low-risk BCC (<2 cm, well-defined, primary, low-risk site): 4 mm margins achieve clearance in 95% of cases.
High-risk BCC (>2 cm, poorly defined, aggressive subtype, recurrent): wider margins and/or Mohs surgery preferred.

Peripheral and deep margin assessment on frozen or permanent sections confirms complete excision.

Topical Therapies

Imiquimod 5% cream (immune response modifier) and 5-fluorouracil cream are FDA-approved for superficial BCC on the trunk and extremities. They are non-surgical alternatives for patients who are poor surgical candidates or who refuse surgery. Clearance rates are lower (75–85%) than surgical approaches and they are not appropriate for nodular or infiltrative subtypes.

Photodynamic Therapy (PDT)

Topical 5-aminolevulinic acid (5-ALA) is applied to the tumor and activated by specific-wavelength light, generating reactive oxygen species that destroy tumor cells. Suitable for superficial BCC; comparable efficacy to surgery for superficial lesions with better cosmetic outcomes. Not appropriate for nodular or deep subtypes.

Radiation Therapy

Radiation is an effective option for patients who cannot undergo surgery (elderly, anticoagulated, complex comorbidities) or where surgery would cause unacceptable functional or cosmetic morbidity (e.g., near the eye). Cure rates are similar to surgery for primary BCC but recurrence rates are higher for previously treated tumors. It is not preferred in young patients due to long-term field changes and the risk of radiation-induced carcinomas decades later.

Mohs Micrographic Surgery

Mohs micrographic surgery is the gold-standard treatment for high-risk BCCs. Developed by Frederic Mohs in the 1930s, the technique involves sequential excision of thin tissue layers with immediate complete margin assessment (100% of the peripheral and deep margins examined on frozen sections), excising more tissue only where cancer remains. This continues until margins are entirely clear.

Indications for Mohs Surgery

High-risk anatomical locations: Face (especially central face, nose, ears, eyelids, lips), hands, feet, genitalia — areas where tissue conservation is critical for function and cosmesis.
Large tumors (>2 cm)
Aggressive histologic subtypes: Morpheaform, infiltrative, basosquamous
Recurrent BCC after previous treatment
Perineural or perivascular invasion
Immunosuppressed patients
Gorlin syndrome

Mohs surgery achieves 5-year cure rates of 99% for primary BCC and 94–95% for recurrent BCC — superior to any other treatment modality. It also removes the minimum amount of normal tissue, which is critical around the eyes and nose.

Advanced and Metastatic BCC

The overwhelming majority of BCCs are cured with local treatment. However, a small subset — those that are very large, deeply invasive, or that occur in immunosuppressed patients — can become locally advanced (invading bone, cartilage, nerves, orbit) or, extremely rarely (<0.1%), metastasize to regional lymph nodes, lungs, or bone.

Hedgehog Inhibitors

For locally advanced or metastatic BCC not amenable to surgery or radiation, the Hedgehog pathway inhibitors are the standard of care:

Vismodegib (Erivedge): First-in-class SMO inhibitor; FDA-approved 2012. In the ERIVANCE trial, objective response rate was 43% in metastatic BCC and 30% in locally advanced BCC. Median duration of response ~7.6 months. Side effects: muscle cramps (71%), alopecia (63%), dysgeusia (taste distortion, 55%), weight loss, fatigue. About 50% of patients discontinue due to side effects.
Sonidegib (Odomzo): Second SMO inhibitor; FDA-approved 2015. Similar efficacy and side-effect profile to vismodegib.

Resistance to vismodegib develops via additional SMO mutations or other pathway bypass mechanisms. Combination approaches (adding PD-1 inhibitors, PI3K pathway blockers) are under investigation.

Immunotherapy

Cemiplimab (anti-PD-1) received FDA approval in 2021 for locally advanced or metastatic BCC that progresses on or is intolerant to Hedgehog inhibitors, achieving response rates of approximately 31%.

Prognosis and Recurrence

BCC is almost never fatal. Metastasis occurs in <0.1% of cases, and even locally advanced BCC is now manageable with targeted therapy. The primary concern is local recurrence, which can be destructive on the face.

Low-risk primary BCC treated with excision or ED&C: 5-year recurrence rate <5%
High-risk primary BCC treated with standard excision: 5-year recurrence rate 8–17%
Mohs surgery for primary BCC: 5-year recurrence rate <1%
Recurrent BCC treated with standard excision: 5-year recurrence rate ~17%
Recurrent BCC treated with Mohs: 5-year recurrence rate ~5%

After treatment, surveillance for recurrence and new primary BCCs is essential. Patients with one BCC have a 44% risk of a second BCC within 3 years. Annual full-body skin examinations by a dermatologist are recommended lifelong.

Prevention and Surveillance

Daily broad-spectrum SPF 30+ sunscreen: Reduces the risk of new BCCs in high-risk populations; a randomized trial demonstrated a 25% reduction in BCC incidence with daily sunscreen use versus discretionary use.
Protective clothing and wide-brimmed hats: More reliable than sunscreen alone for field workers and outdoor athletes.
Avoid tanning beds completely.
Seek shade 10 am–4 pm.
Nicotinamide (vitamin B3): Oral nicotinamide 500 mg twice daily reduced new BCCs by 20% in a randomized trial of high-risk patients (Chen et al., 2015, NEJM). An inexpensive preventive strategy for patients with a history of multiple BCCs.
Annual dermatology skin checks with full-body examination — crucial for high-risk individuals (prior BCC, fair skin, outdoor workers, transplant recipients).
Transplant recipients: Require skin examinations every 6 months due to dramatically elevated risk; field cancerization (widespread UV-damaged skin at risk for multiple tumors) may warrant field-directed therapies (topical 5-FU, PDT, acitretin).

Research Papers

Key peer-reviewed studies on BCC biology, diagnosis, and treatment. Each PMID link opens the study on PubMed.

Sekulic A, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma (ERIVANCE). N Engl J Med. 2012;366(23):2171-2179. PMID 22670903
Chen AC, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618-1626. PMID 26488693
Kauvar AN, et al. Consensus for nonmelanoma skin cancer treatment, part I: basal cell carcinoma. Dermatol Surg. 2015;41(5):550-571. PMID 25868100
Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989;15(3):315-328. PMID 2645597
Green A, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin (Nambour Skin Cancer Prevention Trial). Lancet. 1999;354(9180):723-729. PMID 10475183
Gailani MR, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996;14(1):78-81. PMID 8782823
Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol. 2005;124(3):505-513. PMID 15737192
Puig S, et al. Dermoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol. 2010;62(1):67-75. PMID 19818528
Stratigos AJ, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer. 2020;128:83-102. PMID 32087007
Mohan SV, Chang AL. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr Dermatol Rep. 2014;3(1):40-45. PMID 24587977
Chren MM, et al. Recurrence after treatment of nonmelanoma skin cancer: a prospective cohort study. Arch Dermatol. 2011;147(5):540-546. PMID 21576543
Basset-Seguin N, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729-736. PMID 25981810

Curated PubMed topic searches:

Back to Table of Contents

Connections